Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medical Developments International's Revenue for the
six
months ended in Dec. 2025 was A$21.57 Mil. Medical Developments International's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$7.96 Mil.
Hence, Medical Developments International's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.71.
Medical Developments International (ASX:MVP) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Medical Developments International Receivables Turnover Related Terms
Medical Developments International Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International Receivables Turnover Chart
ASX:MVP vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Medical Developments International's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a Receivables Turnover of 2.71 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medical Developments International and its competitors. According to the industry distribution chart, Medical Developments International ranks #462 out of 950 companies in the Drug Manufacturers industry, placing it in the top 48.6%.
Is Medical Developments International's Receivables Turnover too high?
Medical Developments International's current Receivables Turnover is 2.71. The Drug Manufacturers industry median Receivables Turnover is 5.07. Medical Developments International's value of 2.71 is 46.5% below this industry median. Based on the distribution chart, Medical Developments International ranks #462 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medical Developments International has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #462 out of 950 companies for Receivables Turnover. This puts Medical Developments International in the upper half of its industry. The industry median Receivables Turnover is 5.07. Medical Developments International's value of 2.71 is 46.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current Receivables Turnover of 2.71 is 46.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current Receivables Turnover is 2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.65, compared to a current price of A$0.41 — trading 36.9% below its estimated fair value. The current Receivables Turnover is 2.71 and 46.5% below the Drug Manufacturers industry median of 5.07. Medical Developments International's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current Receivables Turnover is 2.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.41 is trading 36.9% below its estimated GF Value™ of A$0.65.
GuruFocus considers Medical Developments International to be Significantly Undervalued.
Key valuation signals for ASX:MVP:
Receivables Turnover: 2.71
GF Value™: A$0.65 vs. price of A$0.41 (36.9% below fair value)
Industry Position: 46.5% below the Drug Manufacturers median (#462 of 950)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
54GF Score
Get the complete analysis for ASX:MVP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
